In a recent study, gemticabine- and cisplatin-resistant RT112 BC cells were verified to have enhanced cIAP1/2 and XIAP expression and to be cross-resistant to TRAIL-mediated apoptosis. The gene discussed is BIRC2; the disease is breast cancer.